Asset Management One Co. Ltd. Sells 3,980 Shares of Becton, Dickinson and Company $BDX

Asset Management One Co. Ltd. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136,669 shares of the medical instruments supplier’s stock after selling 3,980 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Becton, Dickinson and Company were worth $23,541,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Saudi Central Bank bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Finally, WPG Advisers LLC bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $36,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BDX. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Friday. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 1,838 shares of company stock valued at $348,392 over the last 90 days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $185.85 on Friday. The company’s fifty day simple moving average is $189.93 and its 200-day simple moving average is $183.97. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market cap of $53.27 billion, a PE ratio of 33.43, a P/E/G ratio of 1.45 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.